Ernesto Alonso, MD
Clinical Neurophysiology · Lake City, FLNPI 1396170601
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $181,923 of the $211,135 with a category attached, or 86.2%. AbbVie accounts for 85.0% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2022 at $62,598 and has fallen 67.4% since, to $20,400 in 2025.
Across 1,413 payments — averaging $149.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$180K
- Axsome Therapeutics, Inc.$10K
- Lundbeck LLC$2K
- Ipsen Innovation$2K
- Lilly USA, LLC$1K
- Novartis$1K
- plus $15K from 54 others
Across 134 payments — averaging $2011.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Innovation$270K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$181,92386%
- Travel & lodging$4,9092%
- Food & beverage$23,77411%
- Education$2290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 328 | $555,242 |
| QuliptaAtogepant | 192 | $240,709 |
| Kesimpta PenOfatumumab | 24 | $216,643 |
| Nurtec OdtRimegepant Sulfate | 99 | $155,065 |
| Emgality PenGalcanezumab-Gnlm | 151 | $139,506 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 42 | $107,019 |
| Austedo XrDeutetrabenazine | 20 | $97,178 |
| CopaxoneGlatiramer Acetate | 15 | $85,730 |
| Aimovig AutoinjectorErenumab-Aooe | 101 | $81,377 |
| AptiomEslicarbazepine Acetate | 28 | $39,031 |
| NourianzIstradefylline | 21 | $38,721 |
| Memantine Hcl | 1,429 | $34,511 |
| BotoxOnabotulinumtoxina | 24 | $31,144 |
| Gabapentin | 1,560 | $24,794 |
| MounjaroTirzepatide | 22 | $23,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $179,560 | $827,095544 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone | $836 | $182,90935 claims |
| PfizerNurtec Odt | $584 | $155,06599 claims |
| Grifols USA, LLCGamunex-C | $85 | $107,01942 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $156 | $39,03128 claims |
| Kyowa Kirin, Inc.Nourianz | $417 | $38,72121 claims |
| Lilly USA, LLCMounjaro | $1,124 | $23,56522 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $296 | $21,71813 claims |
| Neurelis, Inc.Valtoco | $201 | $17,10223 claims |
| Upsher-smith Laboratories LLCTopiramate | $101 | $4,230416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Lake City
- Raam SambandamClermont$80K
- Noor YonoStuart$62K
- Rabih KashoutyStuart$34K
- Ellen EdgarSunny Isl Bch$9K
- Sheri BisbyWildwood$6K
- Isabella FerandoMiami$5K
- Joshua MendelsonFort Myers$3K
- Daniela RusoviciPort St John$3K
- Magdalena StepienOrlando$2K
- Suparna KrishnaiengarJacksonville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.